Production Linked Incentive Scheme

1. At a Glance

• PLI is an outcome-based manufacturing incentive scheme — cash incentives (4–6% typically) on incremental sales of goods manufactured in India over a base year [S2][S4].
• Launched in 2020 to operationalise Atmanirbhar Bharat and reduce import dependence in strategic sectors [S2][S4].
• Covers 14 sectors with a cumulative incentive outlay of ₹1.97 lakh crore (~₹1.91 lakh crore commonly cited) [S2][S3].
• Examinable across GS-III (economy, industrial policy, manufacturing) — schemes, ministries, sectoral data are direct prelims fodder.

2. Why in the News

• Dec 2025 status update (PIB, Mar 2026): cumulative investment under PLI crossed ₹2.16 lakh crore, sales ₹20.41 lakh crore, exports ₹8.3 lakh crore, and 14.39 lakh jobs created [S2].
• Pharma PLI: cumulative investment of ₹41,943 crore by Dec 2025 — exceeding the ₹17,275 crore committed target [S1].
• 836 applications approved across the 14 sectors [S2].

3. Background & Evolution

• March 2020: First 3 PLI schemes notified — (i) Large Scale Electronics Manufacturing (mobiles), (ii) Bulk Drugs (KSMs/DIs/APIs), (iii) Medical Devices [S4].
• November 2020: Cabinet approved 10 additional sectors — Auto & Auto Components, Pharma Drugs, Specialty Steel, Telecom & Networking, Electronic/Tech Products, White Goods (ACs & LEDs), Food Products, Textiles (MMF & technical), High-efficiency Solar PV Modules, Advanced Chemistry Cell (ACC) Battery [S4].
• 2021: Pharmaceuticals PLI approved with ₹15,000 crore outlay [S1].
• 2021–22: Drones & Drone Components added → total 14 sectors [S2].
• Predecessor logic: replaces input-subsidy / MEIS-style export incentives (WTO-incompatible) with output-linked, time-bound support.

4. Core Static Facts

• Nodal coordinator: DPIIT, Ministry of Commerce & Industry (overall); individual schemes run by respective line ministries (e.g., MeitY for electronics/semicon; Dept. of Pharmaceuticals under Ministry of Chemicals & Fertilizers for pharma [S1]).
• Total approved outlay: ₹1.97 lakh crore (~US$26 bn) across 14 sectors [S2].
• Tenure: typically 5–6 years per scheme; pharma PLI is a 6-year scheme [S1].
• Incentive basis: % of incremental sales over a defined base year (varies by sector); ACC battery uses PLAC (performance + value-addition slabs).
• 14 sectors: Mobiles & Electronic Components; Bulk Drugs (APIs); Medical Devices; Pharmaceuticals; Telecom & Networking; Electronic/Tech Products; Auto & Auto Components; ACC Batteries; Solar PV Modules; White Goods (AC/LED); Specialty Steel; Food Products; Textiles (MMF & Tech); Drones [S2][S4].
• Outcomes (cum. as of 31 Dec 2025): Investment ₹2.16 lakh cr; Production/Sales ₹20.41 lakh cr; Exports ₹8.3 lakh cr; Jobs 14.39 lakh [S2].

5. Multi-Dimensional Analysis

Economic - Shifts industrial policy from import substitution via tariffs to output-linked manufacturing subsidy; targets share of manufacturing in GDP toward 25% (National Manufacturing Policy aspiration). - Exports of ₹8.3 lakh crore under PLI sectors indicate integration into global value chains, especially mobiles & pharma [S2].

Strategic / Geopolitical - Reduces dependence on China for APIs (Bulk Drugs PLI) and electronics; aligns with China+1 supply-chain diversification. - Semiconductor & ACC battery PLI directly tied to energy security and critical-tech sovereignty.

Administrative - WTO-compatible (incremental sales, not export-contingent). - Line-ministry execution risks siloed implementation; some sectors (e.g., specialty steel, textiles) saw slow uptake versus targets.

Scientific/Technological - Mandates threshold investment + R&D/value-addition floors; pushes domestic value chain build-up in semiconductors, drones, ACC.

Fiscal/Governance - Pay-on-performance design caps fiscal exposure; disbursement only against verified incremental sales — limits leakage versus upfront capex subsidies.

6. Recent Developments (12–18 months)

• March 2026 (PIB): Pharma PLI investment ₹41,943 cr by Dec 2025 — 2.4× committed target of ₹17,275 cr [S1].
• 2025 (PIB): 836 applications approved; cumulative jobs cross 14.39 lakh [S2].
• PLI 2.0 discussions: extension/scope expansion to toys, leather, footwear under consideration (sectoral, not yet 14-sector list).
• Semicon ecosystem: ISM (India Semiconductor Mission) packages complementing PLI for display/semicon fabs.

7. Prelims Hooks

• PLI launched 2020; first 3 sectors notified March 2020 [S4].
• Total approved outlay: ₹1.97 lakh crore across 14 sectors [S2].
• Pharmaceuticals PLI approved in 2021; tenure 6 years; nodal: Dept. of Pharmaceuticals, Min. of Chemicals & Fertilizers [S1].
• Bulk Drugs PLI covers KSMs/DIs/APIs — separate scheme from Pharma PLI [S1].
• DPIIT under Ministry of Commerce & Industry is the overall coordinator; not Finance Ministry.
• ACC Battery PLI implemented by Ministry of Heavy Industries.
• Drones & Drone Components added as the 14th sector (under MoCA).
• Large Scale Electronics Manufacturing PLI notified 01.04.2020 [S4].
• White Goods PLI covers only ACs and LED lights — not refrigerators/washing machines.
• Solar PV PLI is for high-efficiency modules (under MNRE).
• Incentives are paid on incremental sales over base year, not on exports — making it WTO-compatible.
• Cumulative exports under PLI: ₹8.3 lakh crore (Dec 2025) [S2].
• Telecom PLI under Dept. of Telecommunications; Food Products under Ministry of Food Processing Industries.
• Textiles PLI covers MMF (Man-Made Fibre) apparel + fabrics + technical textiles — not cotton.

8. Mains Relevance

• GS-III: Indian Economy → Industrial Policy, Manufacturing, Investment Models; also Science & Tech (semicon/drones).
• GS-II: Government policies for vulnerable sectors / employment.
• Likely stems: 1. "PLI marks a paradigm shift from protectionist industrial policy to performance-linked manufacturing support." Critically examine. 2. "PLI alone cannot deliver manufacturing-led growth without complementary reforms in logistics, power, and labour." Discuss. 3. "Evaluate the contribution of PLI in reducing India's import dependence on China in pharmaceuticals and electronics."

9. Related Topics to Study Next

• Make in India (2014) — overarching umbrella policy.
• National Manufacturing Policy 2011 — 25% GDP target.
• India Semiconductor Mission (ISM) — complements electronics PLI.
• PM GatiShakti & National Logistics Policy — addresses logistics-cost handicap.
• FTA negotiations (UK, EU) — market access for PLI exports.
• National Single Window System (NSWS) — investment facilitation.
• Bulk Drug Parks / Medical Device Parks scheme — parallel infra schemes.
• Atmanirbhar Bharat Abhiyan — parent policy umbrella.

10. Common Errors / Trap Areas

• Wrong ministry: PLI is DPIIT-coordinated, not Finance Ministry; pharma PLI ≠ Health Ministry — it's Dept. of Pharmaceuticals (Chemicals & Fertilizers) [S1].
• Confusing Bulk Drugs PLI with Pharmaceuticals PLI — they are two separate schemes; Bulk Drugs targets KSMs/DIs/APIs [S1].
• Number of sectors: started at 13, later 14 (with Drones); aspirants quote 13 outdated figures.
• White Goods PLI scope: only ACs and LEDs, not all white goods.
• Incentive basis: linked to incremental sales, not exports — important for WTO-compatibility distinction.
• Launch year confusion: scheme announced 2020, not 2021; only some sub-schemes (e.g., pharma) approved in 2021.

11. Sources

• [S1] Production Linked Incentive Scheme (Pharma), PIB, 20 Mar 2026 — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2242927 — (tier 1)
• [S2] PLI Scheme with ₹1.91 Lakh Crore Outlay Drives Strong Industry Participation Across 14 Strategic Sectors, PIB — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2230621 — (tier 1)
• [S3] PLI Schemes for 14 Key Sectors, PIB — https://www.pib.gov.in/PressReleasePage.aspx?PRID=1945155 — (tier 1)
• [S4] Cabinet approves PLI Scheme to 10 key Sectors, PIB — https://www.pib.gov.in/PressReleasePage.aspx?PRID=1671912 — (tier 1)